43 research outputs found
A novel Tn antigen epitopeârecognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma
Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional antiâMUC1 antibody is not useful for the differentiation of malignant lung tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitopeâdefined antibody against cancerâassociated sugar chain structures that specifically recognizes the MUC1 Tn antigen (MUC1âTn ED Ab). In the present study, its potential utility as a diagnostic marker and therapeutic tool for lung adenocarcinoma (ADC) was examined. Immunohistochemical analysis of a lung ADC tissue microarray was performed using the MUC1âTn ED Ab (clone SNâ102), and the results were compared with those of another clone and commercially available MUC1 antibodies. The association between positive immunoreactivity of SNâ102 and clinicopathologic factors was analyzed. Furthermore, the association between MUC1âTn expression and epithelialâmesenchymal transition markers and radiological characteristics was analyzed. Moderate or high MUC1âTn expression (MUC1âTnâH) was observed in 138 (78.9%) of the 175 lung ADC cases. MUC1âTnâH was associated with male sex, cigarette smoking, tumor extension, pleural invasion, and higher preoperative serum carcinoembryonic antigen and cytokeratin 19 fragment levels. Tumors with MUC1âTnâH had higher consolidation/tumor ratios according to computed tomography and greater uptakes of 18Fâfluorodeoxyglucose. A total of 46 (26.9%) of the tumors had mesenchymal features, and MUC1âTn positivity was higher in the mesenchymal group than in the epithelial and intermediate groups (P<0.01 and P<0.01, respectively). Patients with tumors exhibiting MUC1âTnâH had significantly shorter 5âyear overall and diseaseâfree survival times (P=0.011 and P<0.001, respectively). Additionally, MUC1âTnâH was identified as an independent prognostic factor in multivariate analysis (P=0.024). MUC1âTn is specific for lung cancer cells and can improve diagnostic capabilities. Additionally, it may be a potential therapeutic target in lung ADC
Rapid Endolysosomal Escape and Controlled Intracellular Trafficking of Cell Surface Mimetic Quantum-Dots-Anchored Peptides and Glycopeptides
A novel strategy for the development
of a high performance nanoparticules
platform was established by means of cell surface mimetic quantum-dots
(QDs)-anchored peptides/glycopeptides, which was developed as a model
system for nanoparticle-based drug delivery (NDD) vehicles with defined
functions helping the specific intracellular trafficking after initial
endocytosis. In this paper, we proposed a standardized protocol for
the preparation of multifunctional QDs that allows for efficient cellular
uptake and rapid escaping from the endolysosomal system and subsequent
cytoplasmic molecular delivery to the target cellular compartment.
Chemoselective ligation of the ketone-functionalized hexahistidine
derivative facilitated both efficient endocytic entry and rapid endolysosomal
escape of the aminooxy/phosphorylcholine self-assembled monolayer-coated
QDs (AO/PCSAM-QDs) to the cytosol in various cell lines such as human
normal and cancer cells, while modifications of these QDs with cell-penetrating
arginine-rich peptides showed poor cellular uptake and induced self-aggregation
of AO/PCSAM-QDs. Combined use of hexahistidylated AO/PCSAM-QDs with
serglycine-like glycopeptides, namely synthetic proteoglycan initiators
(PGIs), elicited the entry and controlled intracellular trafficking,
Golgi localization, and also excretion of these nanoparticles, which
suggested that the present approach would provide an ideal platform
for the design of high performance NDD systems
Correction: A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes (Chem. Sci. (2020) 11 (4999-5006) DOI: 10.1039/D0SC00317D)
Correction for âA straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopesâ by Hajime Wakui et al., Chem. Sci., 2020, 11, 4999â5006, DOI: 10.1039/D0SC00317D